Rhizen receives USFDA orphan drug designation for cancer drug

The US Food and Drug Administration (USFDA) has granted orphan drug designation for Tenalisib (RP6530) for the treatment of patients with peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a BSE filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3c1f2SX
via IFTTT